BRIEF-Regeneron and Sanofi announce FDA approval of Dupixent
* Regeneron and Sanofi announce FDA approval of Dupixent® (Dupilumab), the first targeted biologic therapy for adults with moderate-to-severe atopic dermatitis
Handbag maker Vera Bradley Inc (VRA.O) posted a lower-than-expected quarterly profit as increased promotions hurt margins, and the company cut its full-year earnings outlook.
The company's shares were down 9 percent at $21.50 in after-market trade.
Vera Bradley, known for its bright paisley and floral prints, said it remains cautious about the second half of the year and now expects to earn between $1.60 and $1.63 per share for the full year. It had earlier forecast between $1.68 and $1.71 per share.
Analysts on average were expecting a profit of $1.69 per share, according to Thomson Reuters I/B/E/S.
Second-quarter profit fell to $13.4 million, or 33 cents per share, from $13.6 million, or 34 cents per share, a year earlier.
Revenue rose 18.5 percent to $123 million. Gross margins dropped to 55.8 percent from 57.5 percent.
Analysts on average had expected earnings of 35 cents per share on revenue of $122.2 million.
Shares of the Fort Wayne, Indiana-based company closed at $23.62 on Wednesday on the Nasdaq.
(Reporting by Aditi Shrivastava in Bangalore; Editing by Maju Samuel)
March 28 International offshore driller Ocean RIG UDW Inc filed for Chapter 15 bankruptcy protection in a U.S. court late Monday, hit by cancellations as major oil producing customers withdrew from deep water projects amid falling oil prices.